TB-500 (Thymosin β4 fragment)

How Thymosin Beta-4 Was Discovered

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Low and colleagues published the complete amino acid sequence of bovine thymosin beta-4 in the Proceedings of the National Academy of Sciences in February 1981, describing it as a thymic hormone. Its principal role as a G-actin sequestering protein was recognised later.

Key facts

Publication
PNAS, February 1981 (PMID 6940133)
First author
Low TL
Source
Bovine thymus
Length
43 residues
Original description
Thymic hormone
Later understanding
G-actin sequestering protein

Where the name comes from

Thymosin refers to the thymus, the tissue the protein was isolated from. It was one of several thymic factors investigated in that era, when the thymus was a major focus of immunological research and preparations from it were expected to contain immune-regulating hormones.

What the 1981 paper reported

The complete amino acid sequence of the bovine protein: 43 residues, fully determined. Establishing a complete sequence in 1981 was substantial work, and it is what makes the paper a foundational reference rather than a preliminary report.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The framing that did not survive

It was described as a thymic hormone. That characterisation has not held: thymosin beta-4 is now understood principally as an intracellular actin-sequestering protein present in many cell types, not as a hormone secreted by the thymus to act elsewhere. This is a normal trajectory for a molecule named before its function was known, and the name outlasted the hypothesis.

Why the reframing matters

A hormone acts at a distance on cells bearing receptors for it. An intracellular actin-binding protein does not. The two imply completely different pharmacology, and the older framing lingers in secondary writing in ways that imply a signalling role the current understanding does not support.

From protein to fragment

TB-500 came much later, once the actin-binding activity had been localised to LKKTETQ and it became practical to synthesise the motif alone. The development code TB-500 belongs to that later phase, not to the 1981 work. That matters, because citing the discovery paper as a TB-500 reference attributes the fragment to research that predates it.

Frequently asked questions

Who discovered thymosin beta-4?

Low and colleagues published the complete bovine sequence in PNAS in February 1981.

Is it really a thymic hormone?

That was the original framing and it has not held. It is now understood principally as an intracellular G-actin sequestering protein found in many cell types.

Was TB-500 part of the 1981 work?

No. The fragment came later, once actin binding had been localised to the LKKTETQ motif.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More TB-500 (Thymosin β4 fragment) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.